Asklepios BioPharmaceutical (AskBio) has acquired BrainVectis, a French company dedicated to the development of gene therapy for neurodegenerative disorders. Founded in 2015, BrainVectis is a spin-off from French national institute for health and medical research (INSERM). Based on work carried out by Nathalie Cartier-Lacave and her team and collaborators…..
Trend Chart on Innovative Bioindustries April 12th FEATURE STORY ● Sirnaomics releases positive interim data from phase II Trial of siRNA candidate studies Sirnaomics, a US-China RNAi therapeutics company, reported on April 9th positive interim results from a Phase II trial of its RNA treatment for non-melanoma skin cancer. STP705…..
Covid-19 et remdesivir : Lettre ouverte de Daniel O’Day, CEO de Gilead Sciences 4 avril 2020. Au cours de la semaine dernière, Gilead a travaillé, en collaboration avec les autorités de santé, à la mise en place de programmes d'accès complémentaires pour mettre à disposition des patients, notre médicament expérimental…..
Remdesivir and Covid-19: an update from Daniel O'Day, chairman and CEO of Gilead April 04, 2020. Over the course of the past week, Gilead has been working in consultation with regulatory authorities to establish additional expanded access programs for remdesivir, our investigational medicine for COVID-19. The programs enable hospitals or…..